Saturday, May 2, 2026

Apple Pushes Back AI Voice Assistant Launch Amid Rising Competition

Apple delays the launch of its AI voice assistant Siri, facing challenges in AI development and competition from rivals.

North Korea’s New IRBM Could Reach Guam—What Does This Mean for Global Security?

North Korea successfully tested a new hypersonic intermediate-range ballistic missile, enhancing its nuclear deterrence capabilities.

Super Micro Posts 9% Gain, Riding NVIDIA’s Rebound After A Dramatic Decline

Super Micro's stock surged 9% after NVIDIA's rebound, reflecting renewed investor confidence following a tumultuous year of setbacks.

Tag: FDA

North KoreaKoreaKimMilitarySouth KoreaAImarketrelationsInternational

GC Biopharma Corp Soars After Eight Years on the Back of Immunodeficiency Drug Alyglo, Posting Results in U.S. Market Push

GC Biopharma Corp breaks its fourth-quarter deficit with ALYGLO's success, achieving $106M in annual revenue and plans for future growth.

HM15275 Clinical Trials: What You Need to Know About This Groundbreaking Obesity Treatment

Hanmi Pharmaceutical's HM15275 enters Phase 2 trial, aiming to revolutionize obesity treatment and diabetes management by 2030.

Novo Nordisk’s Oral Wegovy Tops 3,000 Prescriptions in Its First Week—A Challenge to Injectable GLP-1s

Novo Nordisk's Wegovy oral treatment exceeds 3,000 prescriptions in its debut week, signaling a shift towards oral obesity medications.

Novo Nordisk’s Wegovy Pill Draws 3,000 Prescriptions in Its First Week—Is Oral GLP-1 Here to Stay?

Novo Nordisk's Wegovy oral obesity treatment saw over 3,000 prescriptions in its first week, indicating strong market demand.

ABL206: First-in-Class Dual Antibody Drug Conjugate Approved for Clinical Trials in the U.S. – What This Means for Cancer Treatment

ABL Bio and Neok Bio received FDA approval for ABL206, a dual-antibody ADC, marking a key milestone in their clinical development efforts.

Unlocking the Secrets of Hugel’s 900 Million USD Revenue Goal: A Comprehensive Guide

Hugel aims for 900 billion KRW in U.S. sales by 2028, leveraging a hybrid sales model to capture significant market share.

K-Bio Revolution: How Korean Biopharmaceuticals Are Conquering the Global Market in 2026

South Korea's pharmaceutical industry thrives with innovative drugs like botulinum toxins and cancer treatments, targeting global markets.

How Celltrion Plans to Expand Its Biosimilar Portfolio to 41 Products by 2038

Celltrion unveils its growth strategy at the JP Morgan Healthcare Conference, aiming to expand biosimilars and develop new drug pipelines.

HK inno.N’s New Drug K-CAB Applies for U.S. FDA Approval: How Innovative Is the P-CAB Therapy?

HK inno.N's K-Cap for GERD has entered the U.S. approval process, showing superior results in clinical trials over existing treatments.

HLB’s Liragratinib: A Game-Changer in Cholangiocarcinoma Treatment Revealed at ASCO GI 2026!

HLB's lirafugratinib shows promise as a precision oncology drug, targeting FGFR2 in cancer treatment. FDA application expected soon.

SK Biofarm, FDA Approved Radioactive Method: Will it be a Revolutionary Cancer Cure with SLK 33501?

SK Biopharmaceuticals gains FDA approval for Phase 1 trials of radiopharmaceuticals SKL35501 and SKL35502, advancing cancer treatment.

The Easiest Way To Lose Investor Trust? Just Steal $6.7 Billion! BMS Masterclass In Bad Business

Bristol Myers Squibb faces a $6.7B lawsuit over alleged delays in drug approvals affecting former Celgene shareholders' payouts.

Fever’s Bigger Risk: Why the Tylenol Controversy Puts Moms in a Bind

Controversy surrounds acetaminophen use during pregnancy and its alleged link to autism, but evidence remains inconclusive.

Trump’s Next Target: Big Pharma’s Tylenol. Why He’s Questioning a $1B Industry

Trump links Tylenol to autism risk, announcing new FDA guidelines and studies, but scientific consensus remains unestablished.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.